ArticleJournal of the American Heart Association2026
Mortality, Hospitalization, and Cardiac Interventions Among Patients With Mitral Valve Prolapse <65 Years of Age.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with mitral valves prolapse have a heterogeneous course, and long-term outcomes among those <65 years of age are unclear.
methodsPatients <65 years of age with echocardiographic evidence of MVP at a multihospital academic health system between 2010 and 2024 were evaluated, and all-cause mortality, cardiovascular hospitalization for heart failure, atrial fibrillation, and ventricular arrhythmias (ventricular tachycardia/ventricular fibrillation/sudden cardiac arrest) were ascertained using multivariable Cox proportional hazard modeling and competing risk analysis.
resultsThe study population comprised 4405 patients with MVP (mean age 49±13 years, 16% <35 years of age, 23% 35-50 years of age, 40% men, 92% White) with anterior MVP versus posterior MVP versus bileaflet MVP noted in 34% versus 33% versus 33%, respectively, whereas 16% had moderate or greater mitral regurgitation. Over a median follow-up of 7.8±4 years, 313 patients (7%) died, whereas 11% experienced cardiovascular hospitalization (heart failure: 6.5%, atrial fibrillation: 4%, ventricular tachycardia/ventricular fibrillation/sudden cardiac arrest: 1.4%). Defibrillator implantation was performed in 24 (0.5%), whereas 55 (1.2%) patients underwent surgical mitral valve replacement/repair. Presence of anterior MVP (hazard ratio [HR], 1.7 [95% CI, 1.2-2.4];
conclusionsIn a large contemporary real-world cohort of patients <65 years of age with MVP, the clinical and echocardiographic profile varies by age at presentation and MVP subtype with appreciable morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.